Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc.

Biotechnology • Healthcare • Cambridge, MA, United States • ERNA (NCM)

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

212 582 1199 1035 Cambridge Street, Cambridge, MA 02141, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer - PR Newswire
PR Newswire • Oct 29
ERNA Stock Price and Chart — NASDAQ:ERNA - TradingView — Track All Markets
TradingView — Track All Markets • Nov 3
Ernexa Therapeutics announces 1-for-15 reverse stock split - Yahoo Finance
Yahoo Finance • Jun 11
Ernexa Therapeutics Presents New Preclinical Data on ERNA-101 at ASH Annual Meeting Highlighting Innovative Cell Therapy Potential to Combat Cancer - Quiver Quantitative
Quiver Quantitative • Dec 8
Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa - GlobeNewswire
GlobeNewswire • Oct 1

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Ernexa Therapeutics Inc. had layoffs?
No layoff events have been recorded for Ernexa Therapeutics Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Ernexa Therapeutics Inc. have?
Ernexa Therapeutics Inc. has approximately 6 employees.
What industry is Ernexa Therapeutics Inc. in?
Ernexa Therapeutics Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Ernexa Therapeutics Inc. a publicly traded company?
Yes, Ernexa Therapeutics Inc. is publicly traded under the ticker symbol ERNA on the NCM. The company has a market capitalization of approximately $0.01 billion.
Where is Ernexa Therapeutics Inc. headquartered?
Ernexa Therapeutics Inc. is headquartered in Cambridge, MA, United States at 1035 Cambridge Street, Cambridge, MA 02141, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.